Back to Search
Start Over
SL-401 Mediates Potent Cytotoxicity Against CD123+ AML and MDS with Excess Blasts and Demonstrates Therapeutic Benefit in PDX Model
- Source :
- Blood; December 2016, Vol. 128 Issue: 22 p580-580, 1p
- Publication Year :
- 2016
-
Abstract
- Brooks: Stemline Therapeutics, Inc.: Employment, Equity Ownership, Patents & Royalties. Lozanski:Boehringer Ingelheim: Research Funding; Beckman Coulter: Research Funding; Genentech: Research Funding; Stemline Therapeutics Inc.: Research Funding.
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Volume :
- 128
- Issue :
- 22
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs53024400
- Full Text :
- https://doi.org/10.1182/blood.V128.22.580.580